Serina Therapeutics, Inc. (SER)
- Previous Close
5.89 - Open
5.70 - Bid 5.75 x 900
- Ask 6.04 x 800
- Day's Range
5.85 - 6.00 - 52 Week Range
3.81 - 14.57 - Volume
80,752 - Avg. Volume
11,224 - Market Cap (intraday)
58.309M - Beta (5Y Monthly) --
- PE Ratio (TTM)
1.73 - EPS (TTM)
3.38 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
serinatherapeutics.comRecent News: SER
View MorePerformance Overview: SER
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SER
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SER
View MoreValuation Measures
Market Cap
58.31M
Enterprise Value
54.27M
Trailing P/E
1.73
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
34.28
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-135.82%
Return on Equity (ttm)
--
Revenue (ttm)
51k
Net Income Avi to Common (ttm)
-939k
Diluted EPS (ttm)
3.38
Balance Sheet and Cash Flow
Total Cash (mrq)
4.27M
Total Debt/Equity (mrq)
26.43%
Levered Free Cash Flow (ttm)
-11.33M